# A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma

> **NCT01992653** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 85 (actual)

## Conditions studied

- Lymphoma, Non Hodgkin

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Obinutuzumab
- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Prednisolone
- **DRUG:** Prednisone
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01992653
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-29
- **Primary completion:** 2018-12-19
- **Final completion:** 2018-12-19
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01992653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01992653, "A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01992653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*